Lazard Asset Management
NPCE icon

Lazard Asset Management’s Neuropace NPCE Stock Holding History

Lazard Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Buy
127,728
+3,423
+3% +$55.1K ﹤0.01% 981
2026
Q1 		$1.63M Buy
124,305
+11,078
+10% +$166K ﹤0.01% 993
2025
Q4 		$1.75M Buy
113,227
+8,138
+8% +$109K ﹤0.01% 926
2025
Q3 		$1.08M Buy
105,089
+26,204
+33% +$247K ﹤0.01% 1115
2025
Q2 		$878K Buy
78,885
+75,786
+2,445% +$948K ﹤0.01% 1341
2025
Q1 		$38K Sell
3,099
-308
-9% -$3.85K ﹤0.01% 2036
2024
Q4 		$38K Sell
3,407
-20
-0.6% -$174 ﹤0.01% 2022
2024
Q3 		$23K Buy
3,427
+1
+0% +$7 ﹤0.01% 1993
2024
Q2 		$25K Sell
3,426
-115
-3% -$1.16K ﹤0.01% 2005
2024
Q1 		$46K Sell
3,541
-388
-10% -$5.53K ﹤0.01% 1732
2023
Q4 		$40K Buy
+3,929
New +$31.3K ﹤0.01% 1947

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Lazard Asset Management's NPCE Position: Q2 2026 in Review

Lazard Asset Management increased its Neuropace (NPCE) stake by 2.8% in Q2 2026, buying an estimated $55.1K and bringing the position to 127,728 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Lazard Asset Management first reported a position in NPCE in Q4 2023 and has held it in 11 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Lazard Asset Management held 127,728 shares of Neuropace worth $2.03M as of Q2 2026.
  • Lazard Asset Management bought 3,423 Neuropace shares in Q2 2026, an estimated $55.1K.
  • Neuropace made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #981 holding.
  • Lazard Asset Management first reported a position in Neuropace in Q4 2023 and has held it in 11 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.